GlassScriptPhysician profile
Johnny G Su
NPI 1962422030
$3,679.72
in general payments reported to CMS, 2019-2025
28 companies · $366 in 2025
The $366 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2021: $105 · 2022: $102 · 2023: $1,952 · 2024: $1,010 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,620 · Food and Beverage: $1,565 · Education: $99.99 · Travel and Lodging: $42.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,620.00 |
| Food and Beverage | $1,564.83 |
| Education | $99.99 |
| Travel and Lodging | $42.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,032.33 | 2022-2025 | Tremfya |
| Amgen INC. | $273.80 | 2022-2024 | Krystexxa, Prolia, Evenity |
| Abbvie INC. | $208.15 | 2023-2025 | Rinvoq |
| Horizon Therapeutics Plc | $133.30 | 2019-2023 | Krystexxa |
| Organogenesis INC. | $105.26 | 2021 | |
| Pfizer INC. | $98.66 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $79.61 | 2023-2025 | |
| Radius Health, INC. | $71.07 | 2024 | Tymlos |
| Takeda Pharmaceuticals U.S.A., INC. | $69.78 | 2025 | Trintellix |
| Corcept Therapeutics | $59.10 | 2024 | Korlym |
| Axsome Therapeutics, INC. | $52.44 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $48.19 | 2025 | Rexulti |
| Genentech USA, INC. | $47.19 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.88 | 2024-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $45.89 | 2024 | Trelegy Ellipta, Arexvy, Benlysta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $43.95 | 2024 | Vyepti |
| Phathom Pharmaceuticals, INC. | $34.05 | 2024 | Voquezna |
| Novo Nordisk INC | $31.63 | 2024 | Wegovy |
| Lilly USA, LLC | $30.93 | 2024-2025 | Zepbound, Mounjaro, Taltz |
| Sumitomo Pharma America, INC. | $25.31 | 2024 | Gemtesa |
| Inspire Medical Systems, INC. | $22.13 | 2024 | Inspire |
| Xeris Pharmaceuticals, INC. | $21.24 | 2024 | Gvoke Hypopen |
| Abbott Laboratories | $19.51 | 2025 | Freestyle Libre 3 |
| Sandoz INC. | $19.01 | 2023 | Hyrimoz |
| Corium, LLC | $15.96 | 2024 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $15.05 | 2024 | Breztri |
| Astellas Pharma US INC | $14.98 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $14.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.